Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-05-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/1/e000798corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
by: Xin Sun, et al.
Published: (2020-05-01)

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
by: Lin Li, et al.
Published: (2024-06-01)

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01)

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01)

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
by: Kugeluke Yalikun, et al.
Published: (2025-05-01)

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial
by: Yakun Wang, et al.
Published: (2025-03-01)

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial
by: Xue-Feng Kan, et al.
Published: (2025-05-01)

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
by: Ting Zhang, et al.
Published: (2025-03-01)

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma
by: Zhang J, et al.
Published: (2025-05-01)

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
by: Mingfang Xu, et al.
Published: (2025-07-01)

Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial
by: Hailong Jin, et al.
Published: (2025-07-01)

Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
by: Xiang Zhou, et al.
Published: (2020-01-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC
by: Xiaoling Zhang, et al.
Published: (2025-02-01)

Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis
by: Xiaoxiao Liu, et al.
Published: (2025-07-01)

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial
by: Qinglian Tang, et al.
Published: (2024-09-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
by: Ming Zhang, et al.
Published: (2022-03-01)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
by: Jun Fan, et al.
Published: (2021-11-01)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
by: Yinghui Xu, et al.
Published: (2023-02-01)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
by: Mingtao Liu, et al.
Published: (2020-04-01)

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01)

Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report
by: Zhi-Ping Liu, et al.
Published: (2025-03-01)

Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma
by: Xuesong Li, et al.
Published: (2025-03-01)

Correction: Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
Published: (2022-02-01)

Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Published: (2022-06-01)

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial
by: Tengfei Zhang, et al.
Published: (2025-07-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
by: Yaofei Jiang, et al.
Published: (2025-03-01)

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study
by: Dong Zhao, et al.
Published: (2025-03-01)

PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01)

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study
by: Wu C, et al.
Published: (2025-07-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
by: Zhonghua Zhao, et al.
Published: (2024-12-01)

Matilda, countess of the Perche (1171-1210): the expression of authority in name, style and seal
by: Kathleen Thompson
Published: (2003-07-01)

Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China
by: Zhongqiu Wang, et al.
Published: (2025-02-01)

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
by: Hongtao Duan, et al.
Published: (2024-10-01)

Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report
by: Lixia Yi, et al.
Published: (2023-12-01)

Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial
by: Tao Liu, et al.
Published: (2025-06-01)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Similar Items

Similar Items